Vivax Malaria — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for vivax malaria. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2044. Daily refresh.

1
Approved drugs
2
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Vivax Malaria

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Amivas 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating vivax malaria. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Artesunate
ARTESUNATE
 Amivas 2 65 — 2044-02-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12390442 Artesunate method of use 75 2044-02-16
12121506 Artesunate formulation 55 2044-02-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12121506 Artesunate formulation 55 2044-02-16
12390442 Artesunate method of use 75 2044-02-16

Related